82 results about "Apoptosis protein" patented technology

IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kd of less that 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposes are also disclosed.

Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac / DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language

A unique DHA product, 10, 17S-docosatriene (“Neuroprotectin D1” or “NPD1”), was found to provide surprisingly effective neuroprotection when administered right after an experimental stroke. Moreover, both nerve cells and retinal pigment epithelial (RPE) cells were found to synthesize 10,17S-docosatriene (NPD1) from DHA. NPD1 also potently counteracted H2O2 / TNFα oxidative stress-mediated cell apoptotic damage. Under the same oxidative-stress conditions, NPD1 up-regulated the anti-apoptotic Bcl-2 proteins, Bcl-2 and Bcl-xL, and decreased expression of the pro-apoptotic proteins, Bad and Bax. Moreover, in RPE cells NPD1 inhibited oxidative stress-induced caspase-3 activation, IL-1β-stimulated human COX-2 promoter expression, and apoptosis due to N-retinylidene-N-retinylethanolamine (A2E). Overall, NPD1 protected both nerve and retinal pigment epithelial cells from cellular apoptosis and damage due to oxidative stress. NPD1 concentration in the brain of Alzheimer's patients was found to be significantly decreased from that of controls. In cultured human brain cells, NPD1 synthesis was up-regulated by neuroprotective soluble β amyloid, and NPD1 was found to inhibit secretion of toxic β amyloid peptides.

The invention relates to conformationally constrained mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.

The present invention relates to targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor. In a preferred embodiment, the signal transduction pathway factor is an apoptosis-inducing factor, such as granzyme B, granzyme A, or Bax.

The invention discloses lactobacillus plantarum DP189 and application thereof, and relates to the field of functional food microorganisms. The strain is preserved in China Center for Type Culture Collection on March 25 , 2019 with the preservation number of CCTCC NO:M2019199. By means of the strain, the learning and memory capability of a depressed rat can be improved; the level of brain-derived neurotrophic factors of the depressed rat can be improved; the injury to hippocampal neurons and apoptosis of neuron cells of the depressed rat are reduced; the content of apoptosis proteins JUK2 and Bcl-2 of brain tissue of the depressed rat is lowered; the abundance of verrucomicrobiaceae of the intestinal tract is lowered; the abundance of bacterium lacticum of the intestinal tract is improved, the alpha-diversity of the intestinal floras is improved, and the intestinal flora disturbance of the depressed rat is alleviated. In this way, the lactobacillus plantarum DP189 has good effects of preventing and treating depression / anxiety, infantile autism and inflammatory enteritis. The strain has the anti-depression function, and can serve as a functional probiotic bacterium for preventingand treating the depression, infantile autism and inflammatory enteritis, and a new idea is provided for clinical intervention with and control over depression and other relevant mental diseases.

The invention discloses novel phosphorylation sites identified in signal transduction proteins and pathways, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites / proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor / scaffold proteins, adhesion / extracellular matrix protein, apoptosis proteins, calcium binding proteins, cell cycle regulation proteins, chaperone proteins, chromatin, DNA binding / repair / replication proteins, cytoskeletal proteins, endoplasmic reticulum or golgi proteins, enzyme proteins, G / regulator proteins, inhibitor proteins, motor / contractile proteins, phosphatase, protease, Ser / Thr protein kinases, protein kinase (Tyr)s, receptor / channel / cell surface proteins, RNA binding proteins, transcriptional regulators, tumor suppressor proteins, ubiquitan conjugating system proteins and proteins of unknown function.

The invention discloses nearly 480 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites / proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor / scaffold proteins, acetyltransferases, actin binding proteins, adhesion proteins, apoptosis proteins, calcium-binding proteins, cell cycle regulation proteins, cell surface proteins, channel proteins, chaperone proteins, contractile proteins, cytokine proteins, cytoskeletal proteins, G protein regulators and GTPase activating proteins, guanine nucleotide exchange factors, helicase proteins, immunoglobulin superfamily proteins, inhibitor proteins, protein kinases, lipid kinases, ligases, lipid binding proteins, methytransferases, motor proteins, oxidoreductases, phosphotases, phosphodiesterases, phospholipases, proteases, receptor proteins, trascription factors, transferases, translation / transporter proteins, and ubiquitin conjugating system proteins.

The invention discloses embryo secreting type endogenous polypeptide PDBCM and application thereof. The amino acid sequence of the embryo secreting type endogenous polypeptide PDBCM is as shown in SEQ ID NO.1. The polypeptide PDBCM can enhance BIRC6 expression, reduce apoptosis proteins Smac and reduce caspase-9 expression, thus promoting formation of blastula. The embryo secreting type endogenous polypeptide PDBCM can be applied to preparation of a medicine capable of promoting the formation of the blastula and / or improving the quality of the blastula or preparation of blastula culture liquid in an in vitro fertilization-embryo transplantation process.

The invention discloses novel phosphorylation sites identified in signal transduction proteins and pathways, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites / proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor / scaffold proteins, adhesion / extracellular matrix protein, apoptosis proteins, calcium binding proteins, cell cycle regulation proteins, chaperone proteins, chromatin, DNA binding / repair / replication proteins, cytoskeletal proteins, endoplasmic reticulum or golgi proteins, enzyme proteins, G / regulator proteins, inhibitor proteins, motor / contractile proteins, phosphatase, protease, Ser / Thr protein kinases, Protein kinase (Tyr)s, receptor / channel / cell suface proteins, RNA binding proteins, transcriptional regulators, tumor suppressor proteins, ubiquitan conjugating system proteins and proteins of unknown function.

The invention discloses a self-assembled peptide-apoptin gene composite nanoparticle, and a preparation method and an application thereof. A self-assembled polypeptide is used as a carrier, charges carried by acidic amino acids and alkaline amino acids of the carrier and plasmid molecules carrying the apoptin gene form ionic bonds, and the plasmid molecules are firmly adhered to the surface of the self-assembled polypeptide to form the self-assembled polypeptide-apoptin gene composite nanoparticle. The composite nanoparticle is fibrous, the length is 100-200nm, and the diameter is 10-20nm. The surface of the nanoparticle is rich in arginine, so the nanoparticle can be identified by and combined with an arginine receptor on the surface of a cell membrane, and can be taken by the cell, the gene carried by the nanoparticle can be expressed in the cell, and an expressed apoptosis protein can specifically induce tumor cell apoptosis and is nontoxic to normal cells. The composite nanoparticle is a novel antitumor gene treatment bio-preparation and has a broad application prospect.

Single-domain anti-bodies that bind pro-apoptotic proteins Bax and caspase-3 are identified and isolated. These single-domain antibodies may be used to modulate the active of Bax and caspase-3, thereby modulating the symptoms and steps of oxidative stress and / or cell apoptosis, including Bax dimerization, mitochondrial permeabilization and the release of apoptotic proteins.

The invention discloses an anti-apoptosis Mcl-1 protein inhibitor, and applications thereof, and belongs to the field of medical technology. The anti-apoptosis Mcl-1 protein inhibitor is a 6,7-dihydroxycoumarin derivative, and the general structure is represented by formula (I), wherein R1 and R2 are used for representing H or (C1-C6) alkyl groups, R3 is used for representing H or CH2NR5R6, NR5R6 is one randomly selected from dimethylamine, diethylamine, dipropyl amine, diisopropylamine, pyrrolidine, piperidine, morpholine, piperazine, or structure derivatives thereof, R4 is used for representing one randomly selected from H, (C1-C6) alkyl groups, CF3, OH-(C1-C6) alkyl groups, and halogenated-(C1-C6) alkyl groups. The anti-apoptosis Mcl-1 protein inhibitor is used for inducing cell apoptosis via competitive binding and antagonism with Mcl-1 protein, killing tumor cells, and can be taken as an anticancer medicine. The anti-apoptosis Mcl-1 protein inhibitor is low in molecular weight, excellent in membrane permeable performance, and high in safety, and possessing a promising prospect in development of medicines.

The invention provides a sequence for expressing targeted double-recombinant apoptosis proteins of liver cancer, which is a DNA sequence for regulating the expression of two apoptosis proteins of Caspase 3 and Granzyme B by using a specific AFP promoter, and has a nucleotide sequence shown as SEQID No:1. The sequence utilizes the function of targeted regulation of an AFP enhancer / promoter transcriptional regulatory element to lead foreign gene to be expressed in liver cancer cells with positive AFP, thus realizing targeted and high-efficiency anti-tumor effect; and the sequence constructs recombinant activated type Caspase-3 molecule, applies the recombinant activated type Caspase-3 to pro-apoptotic effect for target cells, introduces granzyme B, fuses the granzyme B and the recombinant activated type Caspase-3 molecule, and mediates the apoptosis of the target cells. The invention also provides an application in preparing targeted gene drugs for treating the liver caner with the positive AFP.

Undifferentiated primordial stem cells are manipulated to permit their long term growth in defined media lacking serum and feeder layer cells by shifting the apoptotic balance of the cells, through increasing the activity of Bcl-2 family anti-apoptotic proteins or decreasing the activity of Bcl-2 family pro-apoptotic proteins. In some embodiments of the invention, the Bcl family protein is Bcl-2. The ES cells sustain the characteristics of undifferentiated, pluripotent stem cells during long-term serum- and feeder layer cell-free conditions, including the ability to be expanded in vitro, but maintain their potential to differentiate into mature cell types.

The invention discloses 432 novel acetylation sites identified in signal transduction proteins and pathways underlying human protein acetylation signaling pathways, and provides acetylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these acetylated sites / proteins, as well as methods of using the reagents for such purpose. Among the acetylation sites identified are sites occurring in the following protein types: Acetyltransferases, Adaptor / Scaffold proteins, Actin binding proteins, Adhesion proteins, Apoptosis proteins, Calcium-binding proteins, Cell Cycle Regulation proteins, Cell Surface proteins, DNA binding proteins, DNA replication proteins, Channel proteins, Chaperone proteins, Cellular Metabolism enzymes, Cytoskeletal proteins, DNA repair proteins, Endoplasmic reticulum proteins, Enzyme proteins, G protein and GTPase Activating proteins, Guanine Nucleotide Exchange Factors, Helicase proteins, Isomerase proteins, Extracelluar matrix proteins, Hydrolases, Ligase proteins, Lipid kinases, Inhibtor proteins, Lipid Binding proteins and Lyases.

The present invention belongs to the field of medical chemistry, relates to a class of compounds of apoptosis protein inhibitors, and applications thereof, and particularly provides a compound represented by a formula I, or an isomer thereof, a pharmaceutically acceptable salt, a solvate, a crystal or a prodrug thereof, preparation methods of the compounds, pharmaceutical compositions containing the compounds, and uses of the compounds or the compositions in treatment and / or prevention of IAPs overexpression related diseases such as viral infections, cancer, hyperblastosis diseases or inflammatory diseases. According to the present invention, the compound has good inhibitory activity against IAPs, and is highly expected to be used as the treatment drug for viral infection, cancer, hyperblastosis diseases or inflammatory diseases. The formula I is defined in the specification.

The invention relates to a composition for preventing and treating amyotrophic lateral sclerosis. The invention discloses a use of homocysteine downregulator in the preparation of a composition for preventing, alleviating or treating the amyotrophic lateral sclerosis of mammal, wherein the downregulator is a folic acid or a mixture of the folic acid and a vitamin B12. The downregulator can effectively alleviate the amyotrophic lateral sclerosis of mammal, reduce the level of inflammatory factors in the spinal cord of mammal, reduce the level of apoptosis protein in the spinal cord, and improvethe level of anti-apoptotic protein in the spinal cord.

The invention discloses novel phosphorylation sites identified in signal transduction proteins and pathways, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites / proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor / scaffold proteins, adhesion / extracellular matrix protein, apoptosis proteins, calcium binding proteins, cell cycle regulation proteins, chaperone proteins, chromatin, DNA binding / repair / replication proteins, cytoskeletal proteins, endoplasmic reticulum or golgi proteins, enzyme proteins, G / regulator proteins, inhibitor proteins, motor / contractile proteins, phosphatase, protease, Ser / Thr protein kinases, Protein kinase (Tyr)s, receptor / channel / cell surface proteins, RNA binding proteins, transcriptional regulators, tumor suppressor proteins, ubiquitan conjugating system proteins and proteins of unknown function.

The invention discloses nearly 443 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human carcinoma, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites / proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Protein kinases (including Serine / Threonine dual specificity, and Tyrosine kinases), Adaptor / Scaffold proteins, Transcription factors, Phospoatases, Tumor supressors, Ubiquitin conjugating system proteins, Translation initiation complex proteins, RNA binding proteins, Apoptosis proteins, Adhesion proteins, G protein regulators / GTPase activating protein / Guanine nucleotide exchange factor proteins, and DNA binding / replication / repair proteins, as well as other protein types.

The invention relates to a Fructus Amomi volatile oil soft capsule for alleviating chemotherapy induced intestinal mucosa damage, provides a use of Fructus Amomi volatile oil in the preparation of drugs for alleviating chemotherapy induced intestinal mucosa damage, and also provides a soft capsule for alleviating chemotherapy induced intestinal mucosa damage, and a preparation method thereof. The soft capsule comprises an effective component Fructus Amomi volatile oil, a matrix, and a soft capsule shell produced from gelatin, glycerin and water according to a ratio of (1-1.5):(0.2-0.8):(1-1.5). The Fructus Amomi volatile oil improves the body weight reduction, the appetite decrease and the diarrhea induced by a chemotherapy drug 5-FU, inhibits the rising of 5-FU induced inflammation factors, reduces the expression of cell apoptosis proteases, inhibits LPS from entering blood, and increases the expression of intestinal tight junction proteins in order to improve the F-5FU induced rat intestinal mucosa barrier damage. The Fructus Amomi volatile oil increase the intestinal probiotics, reduces the relative abundance of conditioned pathogens, improves the imbalance of 5-FU induced intestinal florae, and keeps the relative stability of the intestinal micro-ecology.

The present invention relates to DNAs encoding anti-apoptotic 30K proteins. More particularly, the present invention is directed to 30K protein genes and a recombinant proteins prepared by using novel anti-apoptotic gene obtained from silkworm. The present invention also provides anti-apoptotic health care food, pharmaceutical preparation, additive for cell culture medium, and food supplement.

The invention discloses nearly 443 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human carcinoma, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites / proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Protein kinases (including Serine / Threonine dual specificity, and Tyrosine kinases), Adaptor / Scaffold proteins, Transcription factors, Phospoatases, Tumor supressors, Ubiquitin conjugating system proteins, Translation initiation complex proteins, RNA binding proteins, Apoptosis proteins, Adhesion proteins, G protein regulators / GTPase activating protein / Guanine nucleotide exchange factor proteins, and DNA binding / replication / repair proteins, as well as other protein types.

The invention discloses nearly 123 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites / proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: protein kinases, adaptor / scaffold proteins, phosphatase / phospholipases, G proteins / GTPase activating proteins / guanine nucleotide exchange factors, cellular metabolism enzymes, DNA binding proteins, cytoskeletal proteins, cell cycle regulation proteins, proteases, RNA binding proteins, transcription proteins, translation initiation complex proteins, transferases, ubiquitin conjugating system proteins, vesicle proteins, actin binding proteins, apoptosis proteins, chemokine proteins, enzyme proteins extra cellular matrix proteins, helicases, hydrolases, immunoglobin superfamily proteins, inhibitor proteins, isomerases, ligases, lipid binding proteins, methyltransferases, motor proteins, receptor proteins, and chaperone proteins.

The invention relates to use of Ruxolitinib in preparation of a drug for treating M2 type acute myeloid leukemia with t (8; 21) chromosome translocation, and the in-vitro effective concentration is 1 * 10<-6>-1 *10<-5>M. Drug Ruxolitinib is not only itself has the effect of inhibiting growth and inducing apoptosis on leukemia cell Kasumi-1, and enhances the drug sensitivity of the leukemia cell Kasumi-1 on rsTRAI by up-regulation of mRNA and protein expression level of DR4, up-regulation of cell apoptosis protein Bax expression, activation of apoptosis protein caspase-3 and inhibition of NF-kappa B protein activity. The drug can be used for treating the M2 type acute myeloid leukemia with t (8; 21) chromosome translocation, the new drug for treating the M2 type acute myeloid leukemia with t (8; 21) chromosome translocation is provided, and a new approach for overcoming TRAIL resistance in leukemia cells can be provided.

The invention relates to the field of biological medicines, in particular to application of FG-4592 or a derivative thereof to preparation of drug for preventing acute radiation bone marrow injury. Proved by in vivo experiments, the FG-4592 can obviously increases the survival rate, relieves the degree of damages on a bone marrow hematopoietic system caused by ionizing radiation, reduces the apoptosis rate of bone marrow nucleated cells and spleen cells after radiation, promotes recovery of the hematopoietic system and the like. Proved by in vitro experiments, the FG-4592 can reduce the apoptosis rate of cells after radiation and the damage condition of cell DNA after radiation. Verified by a Western blot method, the FG-4592 can upregulate expression of hypoxia-inducible factors and downregulate expression of apoptosis proteins. Illustrated that the survival rate can be increased by applying the FG-4592 before radiation, the acute radiation bone marrow injury is relieved, the bone marrow nucleated cells are protected, and a new basis is provided for preventing the acute radiation bone marrow injury by the FG-4592.